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Abstract
histocompatibility and immunogenetics laboratories to develop
a comprehensive program for HLA antibody detection and
identification pre and post-transplantation in order to prevent
kidney allograft losses.
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Presence of donor specific antibodies anti-human leukocyte anti-
gen (HLA) is generally a contra-indication for transplantation and
nowadays the identification of these antibodies are part of most
pre-transplantation evaluations. In Portugal, the implemented pro-
tocol for the registration and maintenance of the active list for
kidney transplant includes a complement-dependent cytotoxity
(CDC) panel-reactive antibody (PRA) screening method, and
Luminex technology for detecting and characterizing HLA alloan-
tibodies. Under the current Portuguese kidney allocation system
from deceased donors, implemented in August 2007, deceased
donor kidneys are primarily allocated via ABO identical and time
on dialysis with extra points to hyperimmunized patients, namely
PRA CDC> 50%. Additional risk for the candidate or transplant
organ can be represented by a proposed calculated PRA (cPRA)
based upon unacceptable HLA antigens detected by Luminex to
which the patient has been sensitized. These unacceptable HLA
antigens used to generate cPRA represents a ‘virtual’ crossmatch
(XM). Sensitized patients are less likely to be matched with a
suitable donor organ. Even after clearing the hurdle of procuring
a living donor, it is still possible that this is not sufficient due to
the likelihood of having a XM-positive. In these cases and in the
presence of incompatible blood type between recipients and their
intended living donors, kidney paired donation (KPD) can provide
an answer by facilitating exchanges between willing donors’ kid-
neys. A national Portuguese KPD program, when realized, may
prevent the current loss of a significant number of suitable liv-
ing donors and reduce waiting list time for a deceased donor.
An upgrade of a suggested point system in a Portuguese KPD
program will be the use of cPRA instead of the values of PRA
CDC. In Portugal, the virtual XM approach simply represents the
optimization of an existing technique.
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As a prelude to establishing flow cytometry-based crossmatching
for patients treated with Rituximab, we evaluated the effect of
different concentrations of pronase on the expression of human
leukocyte antigen (HLA)-class I (CI), class II (CII) and CD20.
In all, 15 fresh peripheral blood lymphocyte (PBL) and 5 fresh
splenic lymphocyte preparations were assessed. Each cell pellet
was mixed and incubated for 30 min at 37◦C with 1 ml of pronase
at concentrations of 0.5, 1.0, 1.5 and 2.0 mg/ml in PBS and PBS
only as a control. Antigen expression at each pronase concentra-
tion was evaluated using fluorescent antibodies, viz. anti-HLA-
ABC/FITC (IM1838U), anti-HLA-DR, DQ, DP/RD1 (6604366)
and anti-CD20/PC5 (A07773) (Beckman-Coulter, UK). For both
cell types: average CD20 median channel fluorescence (MCF)
with 0.5 mg/ml pronase dropped to ∼10% of control values and
was negligible with increasing concentrations of pronase there-
after; average CI MCF steadily decreased with increasing pronase
concentration with an average CI MCF of 56% for PBLs and 41%
for spleen cells with 2.0 mg/ml pronase. Average CII MCF, mea-
sured on PBL ‘B cells’, initially decreased to 79% at 0.5 mg/ml
pronase, but then rose steadily to 97% MCF at 2.0 mg/ml pronase.
Of the 15 PBL samples, with increasing pronase concentration, 7
had an increase in CII MCF, 6 a decrease and 2 showed an ini-
tial decrease followed by an increase in MCF. For spleen derived
‘B cells’, average CII MCF increased 30%−40% above control
MCF at all concentrations of pronase. PBL cell counts decreased
with increasing concentrations of pronase – down to 57% of the
control count at 2.0 mg/ml. The total spleen cell count was seem-
ingly unaffected but splenic B-cells decreased with increasing
concentrations of pronase similar to PBLs. Pronase treatment is
clearly suitable for removing lymphocyte CD20. However, HLA
antigen expression and cell viability are also significantly affected
with increasing concentrations. It is clearly vital that pronase con-
centrations and other technical parameters are well validated for
crossmatching.
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Patients suffering from end stage renal disease can be offered
a better quality of life by a transplant. Eurotransplant, the first
international organ exchange organization, offers to up to 20%
of the patient a fully human leukocyte antigen (HLA)-A,-B,-DR
compatible graft. For transplantation of highly sensitized patients
the acceptable mismatch program has shown to be a successful
tool. Patients included in the Acceptable Mismatch (AM) program
must have more 85% panel reactive antibodies and recently we
could demonstrate that this selection leads to distortion of the
Hardy–Weinberg equilibrium (HWE). Here we report on the
HWE development in patients awaiting a first graft (N = 356),
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